Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
This comic conveys the absurdity of overreliance on symptom measures and excessive testing in contemporary clinical decision making and health care practice.
AMA J Ethics. 2020;22(9):E816-817. doi:
10.1001/amajethics.2020.816.
Dr Lisa Fuller joins Ethics Talk to discuss her article: “How Should Organizations and Clinicians Help Marginalized Patients Manage Loneliness as a Harm of Climate Change?”
Clinicians can support shared decision making by assessing patients’ knowledge, eligibility for screening, and preferences for engagement—active, collaborative, or passive—in the decision making process.
AMA J Ethics. 2015;17(7):601-607. doi:
10.1001/journalofethics.2015.17.7.ecas1-1507.